Bicycle Therapeutics, a Phase 1 biotech developing novel oncology medicines based on bicyclic peptides, raised $61 million by offering 4.3 million ADSs at $14, the low end of the range of $14 to $16. Insiders had intended to purchase up to $25 million of the IPO. The UK-based company plans to list on the Nasdaq under the symbol BCYC. Goldman Sachs, Jefferies and Piper Jaffray acted as joint book-running managers on the deal.
